Related Experiment Video

Updated: Jul 8, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Doubting T(h)OMAS: Has the era of precision oncology arrived in uterine leiomyosarcoma?

E A De Jaeghere1, A Dufresne2, L Azarang3

  • 1Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, the Netherlands; Medical Oncology Department, Ghent University Hospital, Ghent, Belgium.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|February 19, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
07:44

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice

Published on: February 17, 2023

Development of Mouse-Derived Organoid Lines from Fallopian Tube Epithelial Cells for High Grade Serous Ovarian Carcinoma Modeling
06:51

Development of Mouse-Derived Organoid Lines from Fallopian Tube Epithelial Cells for High Grade Serous Ovarian Carcinoma Modeling

Published on: August 6, 2025

Related Experiment Videos

Last Updated: Jul 8, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
07:44

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice

Published on: February 17, 2023

Development of Mouse-Derived Organoid Lines from Fallopian Tube Epithelial Cells for High Grade Serous Ovarian Carcinoma Modeling
06:51

Development of Mouse-Derived Organoid Lines from Fallopian Tube Epithelial Cells for High Grade Serous Ovarian Carcinoma Modeling

Published on: August 6, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

From registration to insight: how STRONG AYA transforms registry data to enhance decision-support tools for adolescent and young adult oncology.

ESMO real world data and digital oncology·2026

Independent patient access to imaging digital health records: Oncology patients' and healthcare professionals' views and preferences.

Radiography (London, England : 1995)·2026

Mutation type, tyrosine kinase function in normal cell and tyrosine kinase inhibitor activity in cancers.

Scientific reports·2026

Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative population.

ESMO real world data and digital oncology·2026

Minimum standards of specialist adolescent and young adult (AYA) cancer care units: recommendations and implementation roadmap.

ESMO open·2025

Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing.

ESMO open·2025

Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Efficacy of Cryotherapy in Preventing Taxane-Induced Neuropathy: The CryoPac Randomised Controlled Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us